R&D

PIPELINE

Sovargen will continue to expand competitive pipelines through our
proprietary science and technology.

Sovargen R&D Pipeline
Neurological disorders Brain Tumor
Sovargen R&D Pipeline
Pipeline / Modality / Indication Discovery Preclinical Phase I Phase II Partner
SVG103(paxalisib) Small molecule / TSC2) epilepsy
KAZIA(L/I)
SVG105 ASO / FCD II1) epilepsy
Angelini Pharma
SVG104 Gene therapy / MOGHE3)
Under discussion
SVG301 ASO / LGG4)
SVG304 ASO / GBM5)

SVG103(paxalisib) Small molecule / TSC2) epilepsy

KAZIA(L/I)

SVG105 ASO / FCD II1) epilepsy

Angelini Pharma

SVG104 Gene therapy / MOGHE3)

Under discussion

SVG301 ASO / LGG4)

SVG304 ASO / GBM5)

  • Focal Cortical Dysplasia
  • Tuberous Sclerosis Complex
  • MOGHE: Mild malformation of cortical development
    with Oligodendroglial Hyperplasia and Epilepsy
  • LGG: Low Grade Glioma
  • GBM: Glioblastoma

Partnership

Sovargen will expedite and strengthen drug development with our unique
science and technology and also through open collaboration with global partners.

  • Bioinformatics & Artificial Intelligence

    Sovargen is awaiting its partners to collaborate on articulating root causes and mechanisms of CNS diseases and create a transformational long-term platform.
    Programs for Cooperation
    • Genomic data base target discovery
    • In vitro and in vivo Target validation
    • RNA drugs candidate screening & optimization

  • RNA
    Therapeutics

    Sovargen is awaiting its partners to design and materialize a new gene treatment technology
    Programs for Cooperation
    • ASO, siRNA therapy
    • mRNA therapy
    • chemical modification of ASO, siRNA, mRNA
    • Gene editing

  • Delivery System Development

    Sovargen is awaiting its partners to develop new drug delivery systems by which the in vivo stability and the permeability of the blood-brain barrier or BBB, will be further enhanced.
    Programs for Cooperation
    • Liposome
    • Exosome
    • Viral Vector

  • New Disease Models

    Sovargen is awaiting its partners to build disease-specific animal models with the new gene -editing technology to validate the stability and effectiveness of candidate substances.
    Programs for Cooperation
    • Human brain organoid, iPSC
    • Genetic engineered animal model